 Home > Chemicals Industry > China Chemical > The 2021 performance forecast of listed companies in the pharmaceutical equipment industry is sorted out

The 2021 performance forecast of listed companies in the pharmaceutical equipment industry is sorted out

 Last Update: 2022-02-16
 Source: Internet
 Author: User

Tags

tire technology

chemical engineering schools

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

[ Star Enterprise of Chemical Machinery Equipment Network ] The listed companies in the domestic pharmaceutical equipment industry mainly include Chutian Technology, Tofflon, Xinhua Medical, Canaan Technology, Huasheng, Tailin Bio, Chengyitong, Aoxing Life Technology,
etc.
Up to now, most pharmaceutical machine companies have disclosed their 2021 performance forecasts, and they are basically happy.
The author has briefly sorted out this
.

Chemical Machinery Equipment Net Star Enterprise Chemical Machinery Equipment Pharmaceutical Equipment

Chutian Technology: Net profit is expected to increase by 149.
33%-199.
20%

On January 17, Chutian Technology announced the 2021 annual performance forecast.
The company expects that the net profit attributable to shareholders of listed companies in 2021 will be 500 million to 600 million yuan, an increase of 149.
33%-199.
20% over the same period of the previous year
.

　　Regarding the reasons for the change in performance, the company stated that in recent years, the product series has developed from several original product lines to nearly 20 product lines, and product sales have changed from stand-alone sales to the provision of overall solutions for smart pharmaceutical industrial production equipment.
Transition of smart medical technology solutions
.
The quality of products has been gradually improved, and some products have reached the advanced level in Europe and entered the high-end field, opening up high-end import substitution
.
In addition, during the reporting period, the company focused on the development of biopharmaceutical equipment, has basically completed the layout of biopharmaceutical front-end equipment, and made great achievements in the high-end market and import substitution
.

　　Tofflon: Net profit is expected to increase by 65%-95%

　　On January 10, Tofflon announced its 2021 annual performance forecast.
The company expects to achieve a net profit of 765 million to 904 million yuan attributable to shareholders of listed companies in 2021, an increase of 65% to 95% over the same period last year
.

　　During the reporting period, the company focused on the development strategy of "systematization, internationalization, and digital intelligence", adopted the business model of "equipment + engineering + consumables", vigorously promoted the layout and investment of the three major sectors, and provided global customers with forward-looking and Competitive system solutions for pharmaceutical equipment, food equipment, and cell therapy equipment
.
On the business side, the new products and new markets deployed by the company's business segments over the years have gradually shown results.
The segments such as injections and solid preparations have grown steadily; the segments of biological macromolecules and cell equipment have grown rapidly; on the management side, the company has continued to implement the concept of precise management.
, implement digital transformation and improve management level
.

　　Canaan Technology: Expected performance to be basically flat

　　On January 22, Canaan Technology released the 2021 annual performance forecast, which is expected to be basically flat
.
During the reporting period, the net profit attributable to shareholders of the listed company was 57.
7197 million yuan – 78.
0913 million yuan, compared with 67.
9055 million yuan in the same period last year
.

　　It is reported that during the reporting period, the company actively promoted endogenous growth and extensional development, and gradually implemented the "solid preparation intelligent factory overall solution provider" and the strategic layout of the big health industry; the demand in the downstream pharmaceutical industry was relatively strong, resulting in a steady increase in project orders.

.

　　Tailin Bio: It is expected that the performance will rise in the same direction

　　On January 12, Tailin Bio released the 2021 annual performance forecast, which is expected to increase in the same direction
.
During the reporting period, the net profit attributable to shareholders of the listed company was 58.
07 million yuan to 72.
58 million yuan, an increase of 20.
02%-50% over the same period of the previous year
.
The company said that the main reason for the increase in net profit over the same period of the previous year was that the company's sales revenue continued to grow
.

　　Chengyitong: Net profit is expected to increase by 60.
00%-79.
84%

　　On the evening of January 17, Chengyitong released the 2021 annual performance forecast, and it is expected that the performance will increase in the same direction
.
During the reporting period, the net profit attributable to shareholders of the listed company was 96.
62 million yuan to 108 million yuan, an increase of 60.
00%-79.
84% over the same period of the previous year
.

　　Regarding the reasons for the growth in performance, the company said that during the reporting period, the pharmaceutical manufacturing industry performed well, benefiting from downstream demand, and the intelligent manufacturing business segment was operating steadily.
With the combined promotion of advantageous businesses and new businesses, the company's performance grew
.

　　Aoxing Life Technology: Net profit increased by nearly 711%

　　According to the recent announcement of AUSTAR Life Technology, for the year ended December 31, 2021, the company recorded a net profit of not less than RMB 270 million, an increase of nearly 711% compared with 33.
1 million in 2020
.

　　As for the reason for the sharp increase in performance in 2021, the board of directors of AUSTAR Life Technology attributed it to the increase in company orders in 2021, which resulted in a significant improvement in revenue and gross profit
.

　　Original title: 2021 performance forecast of listed companies in the pharmaceutical equipment industry

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.